Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02751292 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety, Tolerability, and Immunogenicity of the Invaplex Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.
Vaccines (Basel)
January 2025
Leiden University Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over a 20-year period. A challenge to effective Shigella vaccine development has been the low immunogenicity and protective efficacy of candidate Shigella vaccines in infants and young children.
View Article and Find Full Text PDFPrevalence of Salmonella and Shigella species and their multidrug resistance patterns among pediatric populations in Ethiopia: a systematic review and meta-analysis.
BMC Infect Dis
January 2025
Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, P.O. Box: 1145, Ethiopia.
Background: Salmonella and Shigella are major enteric pathogens that cause diarrhea in children worldwide. They are pathogenic microbes that cause significant diarrheal morbidity and mortality in under five children in resource limited countries. Thus, this systemic review and meta-analysis aimed to investigate the prevalence of Salmonella and Shigella species and their multidrug resistance patterns in pediatric populations in Ethiopia.
View Article and Find Full Text PDFPharmacokinetics of tebipenem pivoxil used in children suffering from shigellosis: a pilot study in Bangladesh.
Sci Rep
December 2024
Clinical and Diagnostic Services, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), 68, Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka, Bangladesh.
With increasing antibiotic resistance in gram-negative bacteria, including those causing Shigellosis, evidence of safety and pharmacokinetics data on new oral antibiotics is crucial. We aimed to investigate the safety and pharmacokinetic properties of an oral carbapenem, tebipenem pivoxil, along with it's ability to produce desired results in childhood shigellosis. This randomized pilot clinical trial was conducted at Dhaka Hospital, icddr,b in 2022 between May and September.
View Article and Find Full Text PDFSexually transmitted shigellosis.
Acta Dermatovenerol Alp Pannonica Adriat
December 2024
Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Shigellae can be transmitted through sexual contact, especially among gay, bisexual, and other men who have sex with men (gbMSM). The dynamics and factors contributing to sexual transmission of shigellosis are not yet fully understood. Shigella spp.
View Article and Find Full Text PDFA Recombinant Strain Expressing ETEC Heat-Labile Enterotoxin B Subunit Shows Promise for Vaccine Development via OMVs.
Int J Mol Sci
November 2024
Department of Microbiology and Parasitology, Navarra Medical Research Institute (IdiSNA), University of Navarra, 31008 Pamplona, Spain.
Diarrheal diseases caused by and enterotoxigenic (ETEC) are significant health burdens, especially in resource-limited regions with high child mortality. In response to the lack of licensed vaccines and rising antibiotic resistance for these pathogens, this study developed a recombinant strain with the novel incorporation of the gene for the heat-labile enterotoxin B (LTB) subunit of ETEC directly into 's genome, enhancing stability and consistent production. This approach combines the immunogenic potential of LTB with the antigen delivery properties of outer membrane vesicles (OMVs), aiming to provide cross-protection against both bacterial pathogens in a stable, non-replicating vaccine platform.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!